<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03454555</url>
  </required_header>
  <id_info>
    <org_study_id>PCORI-OPD-1610-37006</org_study_id>
    <nct_id>NCT03454555</nct_id>
  </id_info>
  <brief_title>Integrated Health Services to Reduce Opioid Use While Managing Chronic Pain</brief_title>
  <official_title>Integrated Health Services to Reduce Opioid Use While Managing Chronic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RTI International</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina Health Care System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>RTI International</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Up to one-third of Americans suffer from chronic noncancer pain (CNCP). Opioids are often
      used to treat CNCP. Once on chronic opioid therapy (COT), individuals often continue for
      months or years. Evidence for the effectiveness of COT to treat CNCP is insufficient,
      exposing individuals to known risk. Strategies are needed to reduce/eliminate COT in patients
      who are not benefiting from opioids while ensuring access for those who are.

      The researchers will employ a multisite pragmatic trial using real-time randomization to
      examine the comparative effectiveness of 2 approaches: a guideline-concordant pharmacotherapy
      approach integrated with shared decision making (SDM) (Arm 1) compared with a
      guideline-concordant pharmacotherapy approach integrated with motivational interviewing (MI)
      and cognitive behavioral therapy for chronic pain (CBT-CP) (Arm 2).

      The researchers will examine the impact of the 2 approaches on several outcomes. The study
      will examine which set of patients have greater opioid dose reduction, greater rates of
      opioid discontinuation, improved functioning, and/or lower pain scores. Clinical outcomes
      (opioid dose reduction and time to discontinuation) will be assessed using electronic health
      record data at 4 timepoints: baseline, 6 months, 12 months, and 18 months. Patient-reported
      outcomes, including physical functioning and level of pain, will be measured via patient
      survey at 3 timepoints: baseline, 3 months, and 12 months.

      The study will include patients from North Carolina and Tennessee. The researchers will
      enroll 530 patients in each study arm for a total enrollment of 1,060. This sample size will
      provide robust power to detect clinically important differences in reduction of opioid use
      between the two study arms.

      Analyses will include longitudinal (mixed effects) models to compare the change in outcomes
      from baseline to each timepoint between the two study arms. The project team will explore
      differences in the intervention effect according to participant characteristics such as age,
      sex, baseline pain level, baseline opioid dose, physical comorbidities, mental health
      comorbidities, and a history of substance abuse. Qualitative research methods will be used to
      obtain patient input on their experiences.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design and Approach This is a large-scale randomized pragmatic trial of implementing
      pharmacotherapy guidelines and behavioral interventions in real-world settings. This study
      provides the opportunity to advance the science on effectiveness-implementation hybrid study
      designs because we can assess both clinical effectiveness and implementation issues.

      In this trial, the researchers will examine the comparative effectiveness of two approaches
      to reducing opioid dosages for chronic non-cancer patients (CNCP) who are on chronic opioid
      therapy (COT): shared decision making (SDM) and guideline-concordant pharmacotherapy (Arm 1)
      compared with cognitive behavioral therapy for chronic pain and motivational interviewing
      (CBT-CP+MI) and guideline-concordant pharmacotherapy (Arm 2).

      Rationale:

      Believing that an intervention will have a positive outcome is a key tenet of Social Learning
      Theory and self-efficacy is a main tenet of Bandura's Social Cognitive theory that refers to
      one's belief in their ability to succeed in specific situations. Self-efficacy has
      consistently been demonstrated as a reliable predictor of numerous health-related outcomes
      and is one of the primary constructs targeted by CBT for individuals with chronic pain. We
      posit that enhancing patients' self-efficacy, knowledge, and skills for managing their pain
      will lead to decreases in pain interference, self-reported pain status, and symptoms of
      anxiety and depression. Ultimately, this will lead to increases in physical functioning, and
      for some, decreases in opioid use or discontinuation of opioid use. Our model further
      acknowledges that there are certain benefit-risk tradeoffs involved with this study. For
      example, the intended effect of decreased opioid use in the CBT-CP+MI arm may also result in
      increased reports of pain. Our analyses will explore these and other unintended effects to
      the extent possible. Further, the use of CBT-CP+MI is expected to influence outcomes through
      various other intermediate factors (e.g., reduced negative thought that &quot;nothing can be done
      to help my pain&quot;).

      Aims:

      The research team will examine the impact of the 2 approaches on several outcomes. The study
      will examine which set of patients have greater opioid dose reduction, greater rates of
      opioid discontinuation, improved functioning, and/or lower pain scores.

      The specific aims are:

      Aim 1: To test whether CNCP patients who receive guideline-concordant pharmacotherapy
      integrated with a CBT-CP+MI intervention (Arm 2) have greater opioid dose reduction relative
      to their counterparts, who receive guideline-concordant pharmacotherapy integrated with SDM
      (Arm 1).

      Aim 2: To test whether CNCP patients who receive guideline-concordant pharmacotherapy
      integrated with an CBT-CP+MI intervention (Arm 2) have greater rates of opioid
      discontinuation relative to their counterparts, who receive guideline-concordant
      pharmacotherapy integrated with SDM (Arm 1).

      Aim 3: To test whether CNCP patients who receive guideline-concordant pharmacotherapy
      integrated with an CBT-CP+MI intervention (Arm 2) have improved functioning relative to their
      counterparts, who receive guideline-concordant pharmacotherapy integrated with SDM (Arm 1).

      Aim 4: To test whether CNCP patients who receive guideline-concordant pharmacotherapy
      integrated with an CBT-CP+MI intervention (Arm 2) have lower pain scores relative to their
      counterparts, who receive guideline-concordant pharmacotherapy integrated with SDM (Arm 1).

      The research team chose these comparison arms and outcomes based on input from patients,
      patient advocates, and therapists.

      Timeline:

      The project commenced in February 2018. In 2018, researchers will develop a formal study
      protocol documenting the approach and implementation steps, and then proceed with requesting
      Institutional Review Board (IRB) approval. Researchers will finalize arrangements with
      clinical practices in 2018. The study team will conduct clinician training related to the
      interventions to promote consistency in its delivery across the various clinical practices
      prior to initiating the intervention.

      Recruitment, Screening, Enrollment, and Randomization:

      The proposed study will enroll 530 participants in each arm, from primary care and pain
      clinics at three medical centers. Participants will have used opioids at the level of 50 mg
      or greater daily morphine equivalent doses (MED) for 90 or more days, will not have a
      terminal cancer diagnosis, and will not currently be in psychotherapy.

      Patient recruitment will occur on a rolling basis beginning early in 2019 and last for up to
      26 months. Delivery of the intervention will also occur on a rolling basis with the
      recruitment process. We will identify eligible patients monthly and will invite them to
      participate in the study. Patients who are potentially eligible will be identified through
      electronic health records (EHRs) and contacted by mail and phone with an invitation to
      participate. Interested patients will be met at their next clinic visit by a Research
      Coordinator to complete additional screening, enrollment, and randomization.

      The study will use real-time randomization to limit participant loss prior to treatment.
      Eligible patients will be randomized using a stratified, permuted-block design, as this
      constrained randomization approach ensures balance between treatment groups within each of
      the 3 clinical institutions (our only stratification factor) at the completion of each block.
      Consequently, throughout the trial, the treatment arms will have approximately equal sample
      sizes both within a site and across the study. Patients will be provided study information
      based on their treatment assignment. Patients assigned to Arm 2 will be scheduled for initial
      MI and CBT-CP sessions.

      Interventions:

      In Arm 1, patients and clinicians will engage in Shared Decision Making (SDM). In Arm 2,
      patients will participate in cognitive behavioral therapy for chronic pain (CBT-CP) and
      motivational interviewing (MI).

      Patients in both study arms will receive guideline-concordant pharmacotherapy treatment,
      based on clinical guidelines for opioid therapy for CNCP. Guideline-concordant care specifies
      current best practices for COT, and the treatment will include the following: patient risk
      assessment, including screening for prior substance use disorders; screening for behavioral
      health issues; regular monitoring for pain/analgesia with self-reported pain scores (0 to 10,
      with 10 = worst possible pain) at each visit; urine drug screens; elicitation of adverse
      reactions or aberrant medication behavior; and patient education and goal setting.

      Because this is a pragmatic trial, we will not go to excessive lengths to ensure patient
      adherence, as might be done in an efficacy trial. If a patient misses a session, we will call
      him or her once, as would be done in most clinics.

      Control variables will include demographic characteristics, intervention dosage for a subset
      of the analyses (e.g., number of intervention sessions attended, overall comorbidity using
      the Charlson Comorbidity Index, mental health disorders, and number and type of CNCP
      conditions per ICD-9 (International Statistical Classification of Diseases and Related Health
      Problems 9th edition) codes. Comorbidities will be extracted from EHR data.

      Data Analysis and Reporting:

      In a large pragmatic trial such as the one planned, the probability is small that the groups
      will have imbalance by age, sex, health behaviors, or other measured or unmeasured possible
      confounding factors. Nevertheless, researchers will assess whether randomization has
      successfully created comparable groups by descriptively comparing their baseline demographic
      characteristics and potential confounders, including baseline pain score, comorbidities,
      opioid dosage, and number and type of CNCP conditions.

      Researchers will evaluate clinical outcomes and patient-reported outcomes using longitudinal
      analyses. Analyses will use longitudinal (mixed effects) models to compare opioid dose over
      18 months between the two study arms. Time-to-event models will be used to compare time until
      discontinuation of opiates between study arms. Researchers also will explore differences in
      the intervention effect according to participant characteristics, such as age, sex, baseline
      pain level, baseline opioid dose, and the presence of physical comorbidities, mental health
      comorbidities, or a history of substance abuse.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 31, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomly assigned to one of two intervention arms for the duration of the study. The study will use real-time randomization to limit participant loss prior to treatment. Eligible patients will be randomized using a stratified, permuted-block design, as this constrained randomization approach ensures balance between treatment groups within each of the 3 clinical institutions (our only stratification factor) at the completion of each block. Consequently, throughout the trial, the treatment arms will have approximately equal sample sizes both within a site and across the study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of opioid use</measure>
    <time_frame>Baseline</time_frame>
    <description>Average daily opioid dose in milligrams of morphine equivalent. Briefly, total morphine equivalents for each prescription will be calculated by multiplying the quantity of each prescription by the strength of the prescription (milligrams of opioid per unit dispensed). The quantity-strength product is then multiplied by conversion factors derived from published sources to estimate the milligrams of morphine equivalent to the opioids dispensed in the prescription. The total average dose in morphine equivalents per day supplied is calculated by summing the morphine equivalents for each prescription filled during a given period, and dividing by the number of days supplied. Prescribing data are derived from electronic health records (EHRs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction of opioid use</measure>
    <time_frame>6 months</time_frame>
    <description>Average daily opioid dose in milligrams of morphine equivalent. Briefly, total morphine equivalents for each prescription will be calculated by multiplying the quantity of each prescription by the strength of the prescription (milligrams of opioid per unit dispensed). The quantity-strength product is then multiplied by conversion factors derived from published sources to estimate the milligrams of morphine equivalent to the opioids dispensed in the prescription. The total average dose in morphine equivalents per day supplied is calculated by summing the morphine equivalents for each prescription filled during a given period, and dividing by the number of days supplied. Prescribing data are derived from electronic health records (EHRs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction of opioid use</measure>
    <time_frame>12 months</time_frame>
    <description>Average daily opioid dose in milligrams of morphine equivalent. Briefly, total morphine equivalents for each prescription will be calculated by multiplying the quantity of each prescription by the strength of the prescription (milligrams of opioid per unit dispensed). The quantity-strength product is then multiplied by conversion factors derived from published sources to estimate the milligrams of morphine equivalent to the opioids dispensed in the prescription. The total average dose in morphine equivalents per day supplied is calculated by summing the morphine equivalents for each prescription filled during a given period, and dividing by the number of days supplied. Prescribing data are derived from electronic health records (EHRs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction of opioid use</measure>
    <time_frame>18 months</time_frame>
    <description>Average daily opioid dose in milligrams of morphine equivalent. Briefly, total morphine equivalents for each prescription will be calculated by multiplying the quantity of each prescription by the strength of the prescription (milligrams of opioid per unit dispensed). The quantity-strength product is then multiplied by conversion factors derived from published sources to estimate the milligrams of morphine equivalent to the opioids dispensed in the prescription. The total average dose in morphine equivalents per day supplied is calculated by summing the morphine equivalents for each prescription filled during a given period, and dividing by the number of days supplied. Prescribing data are derived from electronic health records (EHRs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to discontinuation of opioid use</measure>
    <time_frame>Baseline</time_frame>
    <description>Discontinuation will be defined as the first day of a minimum 90-day period with no opioid prescriptions and will be assessed at four timepoints. Data are derived from EHRs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to discontinuation of opioid use</measure>
    <time_frame>6 months</time_frame>
    <description>Time to discontinuation will be defined as the first day of a minimum 90-day period with no opioid prescriptions and will be assessed at four timepoints.. Data are derived from EHRs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to discontinuation of opioid use</measure>
    <time_frame>12 months</time_frame>
    <description>Discontinuation will be defined as the first day of a minimum 90-day period with no opioid prescriptions and will be assessed at four timepoints.. Data are derived from EHRs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to discontinuation of opioid use</measure>
    <time_frame>18 months</time_frame>
    <description>Discontinuation will be defined as the first day of a minimum 90-day period with no opioid prescriptions and will be assessed at four timepoints. Data are derived from EHRs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical functioning</measure>
    <time_frame>Baseline</time_frame>
    <description>PROMIS-PF (Patient-Reported Outcomes Measurement Information System Physical functioning). Assesses self-reported capability rather than actual performance of physical activities. Patient-reported outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical functioning</measure>
    <time_frame>3 months</time_frame>
    <description>PROMIS-PF (Patient-Reported Outcomes Measurement Information System Physical functioning). Assesses self-reported capability rather than actual performance of physical activities. Patient-reported outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical functioning</measure>
    <time_frame>12 months</time_frame>
    <description>PROMIS-PF (Patient-Reported Outcomes Measurement Information System Physical functioning). Assesses self-reported capability rather than actual performance of physical activities. Patient-reported outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain interference on functioning</measure>
    <time_frame>Baseline</time_frame>
    <description>PROMIS-PI (Pain Interference), 8-item Short Form. Assesses extent to which pain interferes with daily functioning. Items measured on 5-point Likert scale. Patient-reported outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain interference on functioning</measure>
    <time_frame>3 months</time_frame>
    <description>PROMIS-PI (Pain Interference), 8-item Short Form. Assesses extent to which pain interferes with daily functioning. Items measured on 5-point Likert scale. Patient-reported outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain interference on functioning</measure>
    <time_frame>12 months</time_frame>
    <description>PROMIS-PI (Pain Interference), 8-item Short Form. Assesses extent to which pain interferes with daily functioning. Items measured on 5-point Likert scale. Patient-reported outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain status</measure>
    <time_frame>Baseline</time_frame>
    <description>PROMIS Pain Intensity Short Form, 3 items. Assesses intensity of pain over the past 7 days. Patient-reported outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain status</measure>
    <time_frame>3 months</time_frame>
    <description>PROMIS Pain Intensity Short Form, 3 items. Assesses intensity of pain over the past 7 days. Patient-reported outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain status</measure>
    <time_frame>12 months</time_frame>
    <description>PROMIS Pain Intensity Short Form, 3 items. Assesses intensity of pain over the past 7 days. Patient-reported outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotional distress</measure>
    <time_frame>Baseline</time_frame>
    <description>PROMIS anxiety, 4-items Short Form. Assesses generalized anxiety/distress over the past 7 days. Items measured on 5-point Likert scale. Patient-reported outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotional distress</measure>
    <time_frame>3 months</time_frame>
    <description>PROMIS anxiety, 4-items Short Form. Assesses generalized anxiety/distress over the past 7 days. Items measured on 5-point Likert scale. Patient-reported outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotional distress</measure>
    <time_frame>12 months</time_frame>
    <description>PROMIS anxiety, 4-items Short Form. Assesses generalized anxiety/distress over the past 7 days. Items measured on 5-point Likert scale. Patient-reported outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depressive symptoms</measure>
    <time_frame>Baseline</time_frame>
    <description>PROMIS depression, 4-item Short Form. Assesses depressive symptoms over the past 7 days. Items measured on 5-point Likert scale. Patient-reported outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depressive symptoms</measure>
    <time_frame>3 months</time_frame>
    <description>PROMIS depression, 4-item Short Form. Assesses depressive symptoms over the past 7 days. Items measured on 5-point Likert scale. Patient-reported outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depressive symptoms</measure>
    <time_frame>12 months</time_frame>
    <description>PROMIS depression, 4-item Short Form. Assesses depressive symptoms over the past 7 days. Items measured on 5-point Likert scale. Patient-reported outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-efficacy to manage and cope with pain</measure>
    <time_frame>Baseline</time_frame>
    <description>Selected items from the Chronic Pain Self-Efficacy Scale. Assesses self-efficacy in managing/coping with pain using a 3-factor scale. Items measured on 5-pt Likert scale. Patient-reported outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-efficacy to manage and cope with pain</measure>
    <time_frame>3 months</time_frame>
    <description>Selected items from the Chronic Pain Self-Efficacy Scale. Assesses self-efficacy in managing/coping with pain using a 3-factor scale. Items measured on 5-pt Likert scale. Patient-reported outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-efficacy to manage and cope with pain</measure>
    <time_frame>12 months</time_frame>
    <description>Selected items from the Chronic Pain Self-Efficacy Scale. Assesses self-efficacy in managing/coping with pain using a 3-factor scale. Items measured on 5-pt Likert scale. Patient-reported outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with pain care</measure>
    <time_frame>Baseline</time_frame>
    <description>Selected items from the Pain Treatment Satisfaction Scale. Assesses current satisfaction with pain management on 5 domains, measured on a 5-point Likert scale. Patient-reported outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with pain care</measure>
    <time_frame>3 months</time_frame>
    <description>Selected items from the Pain Treatment Satisfaction Scale. Assesses current satisfaction with pain management on 5 domains, measured on a 5-point Likert scale. Patient-reported outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with pain care</measure>
    <time_frame>12 months</time_frame>
    <description>Selected items from the Pain Treatment Satisfaction Scale. Assesses current satisfaction with pain management on 5 domains, measured on a 5-point Likert scale. Patient-reported outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1060</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 1 patients will receive guideline-concordant pharmacotherapy based on clinical guidelines for opioid therapy for chronic noncancer pain plus the Shared Decision-Making (SDM) intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2 patients will receive the guideline-concordant pharmacotherapy based on clinical guidelines for opioid therapy for chronic noncancer pain plus the Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain (MI+CBT+CP) Intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Shared Decision Making</intervention_name>
    <description>The Shared Decision Making (SDM) intervention is a behavioral intervention to explore and compare treatment options, assess a patient's values and preferences, and reach a shared decision. The intervention will have both clinician and patient components. The content of the clinician component will be based on the AHRQ (Agency for Healthcare Research and Quality) SHARE Approach, which is a 5-step process for shared decision making that includes exploring and comparing the benefits, harms, and risks of each option through meaningful dialogue about what matters most to the patient. Patients randomized to Arm 1 will have their study visits and opioid use managed by the one or two SDM-trained clinicians at their practice.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain</intervention_name>
    <description>The Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain intervention is an empirically based behavioral pain management behavioral therapy intervention, including MI to enhance motivation for opioid dose reduction or cessation and CBT-CP for pain coping skills enhancement. We anticipate 2 MI sessions that will focus on engaging, focusing, evoking, and planning. We anticipate 8 sessions of CBT-CP, as is standard, delivered in a group setting.</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants will be patients at participating primary care or specialty pain
             management clinics at study sites

          -  Patients will be 18-75 years,

          -  Patients will have used opioids at the level of â‰¥50 mg daily MED for 90 or more days
             (based on EHR data).

          -  Patients will not have a terminal cancer diagnosis

          -  Patients will not currently be in psychotherapy (based on self-report).

        Exclusion Criteria:

          -  Patients whose providers refuse permission will not be eligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauren McCormack, PhD, MSPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>RTI International</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Wagner, MPH</last_name>
    <phone>919-316-3802</phone>
    <email>lwagner@rti.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of North Carolina Health Care System</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Audrina Bunton, MA, LPCS</last_name>
      <phone>919-843-3084</phone>
      <email>audrina_bunton@unc.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Chelminski, MD,MPH,FACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timothy Ives, PharmD,CPP,MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maryam Jowza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Health System</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jasmin Carmona, PhD, LMFT</last_name>
      <phone>919-668-0622</phone>
      <email>jasmin.carmona@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Li-Tzy Wu, RN, ScD, MA</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rowena Dolor, MD, MHS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lynn Bowlby, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Health System</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>27232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia Davidson, MPH</last_name>
      <phone>615-936-4056</phone>
      <email>claudia.davidson@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Kristin A Swygert, PhD, DPT</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gurjeet Birdee, MD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rogelio Coronado, PT, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bernet AC; Willens DE; Bauer MS. Effectiveness -implementation hybrid designes: implications for quality improvement science. Implement Sci. 2013;8(Suppl 1):S2. doi: 10.1186/1748-5908-8-s!-s2.</citation>
  </reference>
  <reference>
    <citation>Bandura A. Social learning theory. Englewood Cliffs, NJ: Prentice Hall; 1977</citation>
  </reference>
  <reference>
    <citation>Bandura A.Social foundations of thought and action: A social cognitive theory: Prentice-Hall, Inc.; 1986</citation>
  </reference>
  <reference>
    <citation>Holden G. The relationship of self-efficacy appraisals to subsequent health related outcomes: a meta-analysis. Soc Work Health Care. 1991;16(1):53-93.</citation>
    <PMID>1839087</PMID>
  </reference>
  <reference>
    <citation>Ehde DM, Dillworth TM, Turner JA. Cognitive-behavioral therapy for individuals with chronic pain: efficacy, innovations, and directions for research. Am Psychol. 2014 Feb-Mar;69(2):153-66. doi: 10.1037/a0035747. Review.</citation>
    <PMID>24547801</PMID>
  </reference>
  <reference>
    <citation>Agency Medical Directors' Group. Interagency guideline on opioid dosing for chronic non-cancer pain (CNP)::2010 update. 2010</citation>
  </reference>
  <reference>
    <citation>Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, Donovan MI, Fishbain DA, Foley KM, Fudin J, Gilson AM, Kelter A, Mauskop A, O'Connor PG, Passik SD, Pasternak GW, Portenoy RK, Rich BA, Roberts RG, Todd KH, Miaskowski C; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009 Feb;10(2):113-30. doi: 10.1016/j.jpain.2008.10.008.</citation>
    <PMID>19187889</PMID>
  </reference>
  <reference>
    <citation>The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society. Clin J Pain. 1997 Mar;13(1):6-8.</citation>
    <PMID>9084947</PMID>
  </reference>
  <reference>
    <citation>Edlund MJ, Martin BC, Russo JE, DeVries A, Braden JB, Sullivan MD. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. Clin J Pain. 2014 Jul;30(7):557-64. doi: 10.1097/AJP.0000000000000021.</citation>
    <PMID>24281273</PMID>
  </reference>
  <reference>
    <citation>Kerns RD, Burns JW, Shulman M, Jensen MP, Nielson WR, Czlapinski R, Dallas MI, Chatkoff D, Sellinger J, Heapy A, Rosenberger P. Can we improve cognitive-behavioral therapy for chronic back pain treatment engagement and adherence? A controlled trial of tailored versus standard therapy. Health Psychol. 2014 Sep;33(9):938-47. doi: 10.1037/a0034406. Epub 2013 Dec 2.</citation>
    <PMID>24295024</PMID>
  </reference>
  <reference>
    <citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.</citation>
    <PMID>3558716</PMID>
  </reference>
  <reference>
    <citation>Rosenberg JM, Bilka BM, Wilson SM, Spevak C. Opioid Therapy for Chronic Pain: Overview of the 2017 US Department of Veterans Affairs and US Department of Defense Clinical Practice Guideline. Pain Med. 2018 May 1;19(5):928-941. doi: 10.1093/pm/pnx203.</citation>
    <PMID>29025128</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2018</study_first_submitted>
  <study_first_submitted_qc>March 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2018</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pragmatic Clinical Trial</keyword>
  <keyword>Comparative Effectiveness Research</keyword>
  <keyword>Analgesics, Opioid</keyword>
  <keyword>Decision Making, Shared</keyword>
  <keyword>Motivational Interviewing</keyword>
  <keyword>Cognitive Therapy</keyword>
  <keyword>Patient Reported Outcome Measures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

